Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 4-17

  Swaika, Abhisek ^a   Hammond, William A ^a   Joseph, Richard W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer; Immune evasion; Immunotherapy; PD 1; PD L1

Indexed keywords

BIOLOGICAL MARKER; BMS 936559; DURVALUMAB; ERLOTINIB; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ADVANCED CANCER; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; FOLLICULAR LYMPHOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE EVASION; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; MELANOMA; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME; TRENDS;

SCOPUS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN BINDING; TREATMENT OUTCOME;

EID: 84930730522     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.02.009     Document Type: Review

References (131)

1. Abiko K., Mandai M., Hamanishi J., et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin. Cancer Res. 2013, 19:1363-1374.
2. Ahmadzadeh M., Johnson L.A., Heemskerk B., et al. Tumor antigen-specific CD8T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
3. Alexandroff A.B., Jackson A.M., O'Donnell M.A., et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999, 353:1689-1694.
4. Amin A., Plimack E.R., Infante J.R., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meet. Abstr. 2014, 32:5010.
5. Andorsky D.J., Yamada R.E., Said J., et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res. 2011, 17:4232-4244.
6. Ansell S.M., Lesokhin A.M., Borrello I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015, 372:311-319.
7. Antonia S.J., Gettinger S.N., Chow L.Q.M., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. ASCO Meet. Abstr. 2014, 32:8023.
8. Antonia S.J., Brahmer J.R., Gettinger S.N., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). ASCO Meet. Abstr. 2014, 32:8113.
9. Armand P., Nagler A., Weller E.A., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large b-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 2013, 31:4199-4206.
10. Atkins M.B., Kudchadkar R.R., Sznol M., et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. ASCO Meet. Abstr. 2014, 32:9001.
11. Badoual C., Hans S., Merillon N., et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013, 73:128-138.
12. Barber D.L., Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8T cells during chronic viral infection. Nature 2006, 439:682-687.
13. Benson D.M., Bakan C.E., Mishra A., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010, 116:2286-2294.
14. Berger R., Rotem-Yehudar R., Slama G., et al. Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14:3044-3051.
15. Berghoff A.S., Ricken G., Widhalm G., et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin. Neuropathol. 2014, 33:42-49.
16. Blazar B.R., Carreno B.M., Panoskaltsis-Mortari A., et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J. Immunol. 2003, 171:1272-1277.
17. Boorjian S.A., Sheinin Y., Crispen P.L., et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin. Cancer Res. 2008, 14:4800-4808. (an official journal of the American Association for Cancer Research).
18. Brahmer J.R., Drake C.G., Wollner I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
19. Brahmer J.R., Tykodi S.S., Chow L.Q.M., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
20. Brahmer J.R., Horn L., Gandhi L., et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. ASCO Meet. Abstr. 2014, 32:8112.
21. Brahmer J.R., Rizvi N.A., Lutzky J., et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. ASCO Meet. Abstr. 2014, 32:8021.
22. Carreras J., Lopez-Guillermo A., Roncador G., et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J. Clin. Oncol. 2009, 27:1470-1476.
23. Chen D.S., Irving B.A., Hodi F.S. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 2012, 18:6580-6587.
24. Chen B.J., Chapuy B., Ouyang J., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 2013, 19:3462-3473.
25. Choueiri T.K., Fay A.P., Gray K.P., Callea M., Ho T.H., Albiges L., Bellmunt J., Song J., Carvo I., Lampron M., Stanton M.L., Hodi F.S., McDermott D.F., Atkins M.B., Freeman G.J., Hirsch M.S., Signoretti S. PD-L1 expression in non-clear cell renal cell carcinoma. Ann. Oncol. 2014, 25(11):2178-2184. Epub 2014 Sep 5. PMID: 25193987 [PubMed - in process]. 10.1093/annonc/mdu445.
26. Chow L.Q.B.B., Weiss J., Berger R., Eder J.P., Gonzalez E.J., Pulini J., Johnson J., Dolled-Filhart M., Emancipator K., Lunceford J.K., Pathiraja K., Gause C., Cheng J.D., Seiwert T. LBA31-a phase Ib study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with human papiilloma virus (HPV)-positive and negative head and neck cancer. Ann. Oncol. 2014, 25:1-41. (Official journal of the European Society for Medical Oncology/ESMO).
27. Clemente C.G., Mihm M.C., Bufalino R., et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
28. Curiel T.J., Wei S., Dong H., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
29. Curran M.A., Montalvo W., Yagita H., et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4275-4280.
30. Dasanu C.A., Sethi N., Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin. Biol. Ther. 2012, 12:923-937.
31. Daud A.I., Hamid O., Ribas A., et al. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome [abstract]. Proc. Ann. Meeting AACR 2014, CT104.
32. Dong H., Zhu G., Tamada K., et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 1999, 5:1365-1369.
33. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800.
34. Dorfman D.M., Brown J.A., Shahsafaei A., et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 2006, 30:802-810.
35. Duraiswamy J., Kaluza K.M., Freeman G.J., et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013, 73:3591-3603.
36. Duraiswamy J., Freeman G.J., Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013, 73:6900-6912.
37. Elpek K.G., Lacelle C., Singh N.P., et al. CD4+ CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 2007, 178:6840-6848.
38. Fay A.P., Callea M., Gray K.P., et al. PD-L1 expression in non-clear cell renal cell carcinoma. J. Clin. Oncol. 2014, 32.
39. Finn L., Markovic S.N., Joseph R.W. Therapy for metastatic melanoma: the past, present, and future. BMC Med. 2012, 10(23). http://www.biomedcentral.com/1741-7015/10/2.
40. Francisco L.M., Salinas V.H., Brown K.E., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206:3015-3029.
41. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
42. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 1995, 13:688-696.
43. Gadiot J., Hooijkaas A.I., Kaiser A.D., et al. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011, 117:2192-2201.
44. Gandhi L. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression [abstract]. Proc. Ann. Meet. AACR 2014, CT105.
45. Gangadhar T.C., Vonderheide R.H. Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 2014, 11:91-99.
46. Garon E.B., Leighl N.B., Rizvi N.A., et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meet. Abstr. 2014, 32:8020.
47. Gettinger S.N., Shepherd F.A., Antonia S.J., et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. ASCO Meet. Abstr. 2014, 32:8024.
48. Greaves P., Gribben J.G. The role of B7 family molecules in hematologic malignancy. Blood 2013, 121:734-744.
49. Green M.R., Monti S., Rodig S.J., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116:3268-3277.
50. Grzywnowicz M., Zaleska J., Mertens D., et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS ONE 2012, 7.
51. Hallett W.H.D., Jing W., Drobyski W.R., et al. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol. Blood Marrow Transpl. 2011, 17:1133-1145.
52. Hamanishi J., Mandai M., Iwasaki M., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:3360-3365.
53. Hamanishi J., Mandai M., Ikeda T., et al. Efficacy and safety of anti-PD-1 antibody (nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. ASCO Meet. Abstr. 2014, 32:5511.
54. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
55. Hammers H.J., Plimack E.R., Infante J.R., et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meet. Abstr. 2014, 32:4504.
56. Hardy B., Kovjazin R., Raiter A., et al. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:5756-5760.
57. Herbst R.S., Gordon M.S., Fine G.D., et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J. Clin. Oncol. 2013, 31.
58. Herbst R.S., Soria J-C., Kowanetz M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
59. Herr H.W., Bean M.A., Whitmore W.F. Decreased ability of blood leukocytes from patients with tumors of the urinary bladder to act as stimulator cells in mixed leukocyte culture. Cancer Res. 1976, 36:2754-2760.
60. Hersey P., Ribas A., Hodi F.S., et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma. Asia-Pac. J. Clin. Oncol. 2014, 10:48-49.
61. Hirano F., Kaneko K., Tamura H., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005, 65:1089-1096.
62. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
63. Hodi F.S., Sznol M., Kluger H.M., et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. ASCO Meet. Abstr. 2014, 32:9002.
64. Holt G.E., Podack E.R., Raez L.E. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy 2011, 8:43-54.
65. Inman B.A., Sebo T.J., Frigola X., et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007, 109:1499-1505.
66. Iwai Y., Ishida M., Tanaka Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12293-12297.
67. Iwai Y., Terawaki S., Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 2005, 17:133-144.
68. Jadus M.R., Natividad J., Mai A., et al. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin. Dev. Immunol. 2012, 2012. Article ID 160724, 21 pages. 10.1155/2012/160724.
69. Johnson D.B., Wallender E.K., Cohen D.N., et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol. Res. 2013, 1:373.
70. Joseph R.W., Peddareddigari V.R., Liu P., et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin. Cancer Res. 2011, 17:4882-4891.
71. Joseph R.W., Parasramka M., Eckel-Passow J.E., et al. Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. Cancer Immunol. Res. 2013, 1:378-385.
72. Joseph R.W., Cappel M., Goedjen B., Gordon M., Kirsch B., Gilstrap C., Bagaria S., Jambusaria-Pahlajani A. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol. Res. 2015, 3(1):18-22. Epub 2014 Oct 6. 10.1158/2326-6066.CIR-14-0134.
73. Jure-Kunkel M., Selby M., Lewis K., et al. Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models. ASCO Meet. Abstr. 2013, 31:3019.
74. Koestner W., Hapke M., Herbst J., et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. Blood 2011, 117:1030-1041.
75. Kong C.S., Narasimhan B., Cao H., et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:553-561.
76. Kozako T., Yoshimitsu M., Fujiwara H., et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009, 23:375-382.
77. Krambeck A.E., Dong H., Thompson R.H., et al. Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin. Cancer Res. 2007, 13:1749-1756.
78. Krempski J., Karyampudi L., Behrens M.D., et al. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J. Immunol. 2011, 186:6905-6913.
79. Latchman Y., Wood C.R., Chernova T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2:261-268.
80. Liu J., Hamrouni A., Wolowiec D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110:296-304.
81. Lyford-Pike S., Peng S., Young G.D., et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013, 73:1733-1741.
82. Mangsbo S.M., Sandin L.C., Anger K., et al. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J. Immunother. 2010, 33:225-235.
83. Marincola F.M., Jaffee E.M., Hicklin D.J., et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000, 181-273.
84. Mukamel E., Shohat B., Servadio C. Immunological profile of patients with transitional cell carcinoma of the bladder. Br. J. Urol. 1982, 54:11-15.
85. Munir S., Andersen G.H., Woetmann A., et al. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 2013, 27:2251-2253.
86. Myklebust J.H., Irish J.M., Brody J., et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 2013, 121:1367-1376.
87. Nishimura H., Nose M., Hiai H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
88. Okudaira K., Hokari R., Tsuzuki Y., et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int. J. Oncol 2009, 35:741-749.
89. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
90. Parsa A.T., Waldron J.S., Panner A., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 2007, 13:84-88.
91. Plimack E.R., Gupta S., Bellmunt J., et al. LBA23-a phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer. Ann. Oncol. 2014, 25:1-41. (Official journal of the European Society for Medical Oncology/ESMO).
92. Powles T., Vogelzang N.J., Fine G.D., et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Meet. Abstr. 2014, 32:5011.
93. Powles T., Eder J.P., Fine G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
94. Pyrhönen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 1999, 17:2859-2867.
95. Ramsay A.G., Clear A.J., Fatah R., et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012, 120:1412-1421.
96. Ramsay A.G. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br. J. Haematol. 2013, 162:313-325.
97. Ribas A., Chmielowski B., Glaspy J.A. Do we need a different set of response assessment criteria for tumor immunotherapy?. Clin. Cancer Res. 2009, 15:7116-7118.
98. Rizvi N.A., Garon E.B., Patnaik A., et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meet. Abstr. 2014, 32:8007.
99. Rizvi N.A., Chow L.Q.M., Borghaei H., et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. ASCO Meet. Abstr. 2014, 32:8022.
100. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., Patnaik A., Dronca R., Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus C., Postow M.A., Gergich K., Elassaiss-Schaap J., Li X.N., Iannone R., Ebbinghaus S.W., Kang S.P., Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384(9948):1109-1117. Epub 2014 Jul 15. 10.1016/S0140-6736(14)60958-2.
101. Robert C., Long G.V., Brady B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372:320-330.
102. Rossille D., Gressier M., Damotte D., et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. LID 2014, 10.1038/leu.2014.137.
103. Saudemont A., Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 2004, 104:2124-2133.
104. Saudemont A., Buffenoir G., Denys A., et al. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia 2002, 16:1637-1644.
105. Seiwert T.Y., Burtness B., Weiss J., et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. ASCO Meet. Abstr. 2014, 32:6011.
106. Spigel D.R., Gettinger S.N., Horn L., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). ASCO Meet. Abstr. 2013, 31:8008.
107. Steidl C., Shah S.P., Woolcock B.W., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471:377-383.
108. Strome S.E., Dong H., Tamura H., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003, 63:6501-6505.
109. Sznol M., Kluger H.M., Callahan M.K., et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). ASCO Meet. Abstr. 2014, 32:LBA9003.
110. Taube J.M., Anders R.A., Young G.D., et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012, 4(127):127-137.
111. Thompson R.H., Gillett M.D., Cheville J.C., et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:17174-17179.
112. Thompson R.H., Kuntz S.M., Leibovich B.C., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006, 66:3381-3385.
113. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
114. Topalian S.L., Sznol M., McDermott D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014, 32:1020-1030.
115. Vasilakopoulou M., Velcheti V., Rampias T., et al. Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma. ASCO Meet. Abstr. 2013, 31:6012.
116. Wang W., Lau R., Yu D., et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells. Int. Immunol. 2009, 21:1065-1077.
117. Wang L., Qian J., Lu Y., et al. Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 2013, 98:1458-1466.
118. Webster W.S., Thompson R.H., Harris K.J., et al. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J. Immunol. 2007, 179:2860-2869.
119. West E.E., Jin H.T., Rasheed A.U., et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Investig. 2013, 123:2604-2615.
120. Westin J.R., Chu F., Zhang M., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014, 15:69-77.
121. Wolchok J.D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 2009, 15:7412-7420.
122. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
123. Wong R.M., Scotland R.R., Lau R.L., et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol. 2007, 19:1223-1234.
124. Woo E.Y., Yeh H., Chu C.S., et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 2002, 168:4272-4276.
125. Woo S.R., Turnis M.E., Goldberg M.V., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012, 72:917-927.
126. Xerri L., Chetaille B., Seriari N., et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum. Pathol. 2008, 39:1050-1058.
127. Xylinas E., Robinson B.D., Kluth L.A., et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur. J. Surg. Oncol. 2014, 40:121-127. (The journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology).
128. Yamamoto R., Nishikori M., Kitawaki T., et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008, 111:3220-3224.
129. Yang J.C., Childs R. Immunotherapy for renal cell cancer. J. Clin. Oncol. 2006, 24:5576-5583.
130. Zhang Y., Huang S., Gong D., et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell. Mol. Immunol. 2010, 7:389-395.
131. Zhou Q., Xiao H., Liu Y., et al. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J. Immunol. 2010, 185:5082-5092.